ES2645028A1 - Preparación farmacéutica única y estable que contiene berberina, en formulación de liberación lenta, una estatina y ubiquinol para el tratamiento de la enfermedad cardiovascular y los factores de riesgo asociados - Google Patents

Preparación farmacéutica única y estable que contiene berberina, en formulación de liberación lenta, una estatina y ubiquinol para el tratamiento de la enfermedad cardiovascular y los factores de riesgo asociados Download PDF

Info

Publication number
ES2645028A1
ES2645028A1 ES201731206A ES201731206A ES2645028A1 ES 2645028 A1 ES2645028 A1 ES 2645028A1 ES 201731206 A ES201731206 A ES 201731206A ES 201731206 A ES201731206 A ES 201731206A ES 2645028 A1 ES2645028 A1 ES 2645028A1
Authority
ES
Spain
Prior art keywords
ubiquinol
statin
treatment
unique
slow
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES201731206A
Other languages
English (en)
Other versions
ES2645028B2 (es
Inventor
Maria D. GÓMEZ GARRE
Luca Severino VOLONTÉ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSP
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to ES201731206A priority Critical patent/ES2645028B2/es
Publication of ES2645028A1 publication Critical patent/ES2645028A1/es
Application granted granted Critical
Publication of ES2645028B2 publication Critical patent/ES2645028B2/es
Priority to PCT/ES2018/070666 priority patent/WO2019073103A1/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Preparación farmacéutica única y estable que contiene berberina, en formulación lenta, con una estatina y ubiquinol para el tratamiento de la enfermedad cardiovascular y de sus factores de riesgo asociados. La combinación de berberina, en una formulación de liberación lenta para asegurar su bioasimilación, recubierta de una matriz de estatina y ubiquinol en una presentación única con calidad medicamento constituirá un tratamiento de alta eficacia y más barato que los actuales. La combinación de distintos mecanismos de acción complementarios, permitirá disminuir la dosis de estatina, lo cual se traducirá en menos efectos secundarios, también reducidos por el suplemento en ubiquinol (coenzima Q10), por lo que sería una formulación más saludable. La administración será oral, por lo que se evitarán los pinchazos que siempre son muy impopulares entre los pacientes. Finalmente, la presencia de todos los componentes en un único medicamento favorecerá aún más la adhesión al tratamiento.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6

Claims (1)

  1. imagen1
ES201731206A 2017-10-13 2017-10-13 Preparación farmacéutica única y estable que contiene berberina, en formulación de liberación lenta, una estatina y ubiquinol para el tratamiento de la enfermedad cardiovascular y los factores de riesgo asociados Active ES2645028B2 (es)

Priority Applications (2)

Application Number Priority Date Filing Date Title
ES201731206A ES2645028B2 (es) 2017-10-13 2017-10-13 Preparación farmacéutica única y estable que contiene berberina, en formulación de liberación lenta, una estatina y ubiquinol para el tratamiento de la enfermedad cardiovascular y los factores de riesgo asociados
PCT/ES2018/070666 WO2019073103A1 (es) 2017-10-13 2018-10-15 Composición farmacéutica para el tratamiento de enfermedades cardiovasculares

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201731206A ES2645028B2 (es) 2017-10-13 2017-10-13 Preparación farmacéutica única y estable que contiene berberina, en formulación de liberación lenta, una estatina y ubiquinol para el tratamiento de la enfermedad cardiovascular y los factores de riesgo asociados

Publications (2)

Publication Number Publication Date
ES2645028A1 true ES2645028A1 (es) 2017-12-01
ES2645028B2 ES2645028B2 (es) 2018-06-04

Family

ID=60423051

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201731206A Active ES2645028B2 (es) 2017-10-13 2017-10-13 Preparación farmacéutica única y estable que contiene berberina, en formulación de liberación lenta, una estatina y ubiquinol para el tratamiento de la enfermedad cardiovascular y los factores de riesgo asociados

Country Status (2)

Country Link
ES (1) ES2645028B2 (es)
WO (1) WO2019073103A1 (es)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001052822A1 (en) * 2000-01-20 2001-07-26 Chopra Raj K Reduced form of coenzyme q in high bioavailability stable dosage forms and related applications
WO2007090289A1 (en) * 2006-02-09 2007-08-16 National Research Council Of Canada Combinations of botanical extracts for promoting cardiovascular health
WO2014128639A1 (en) * 2013-02-21 2014-08-28 Rondi Andrea Composition for the treatment of metabolic disorders
US20170135995A1 (en) * 2015-11-13 2017-05-18 Shenzhen Hightide Biopharmaceutical, Ltd. Pharmaceutical compositions of berberine with epa and dha, and methods thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1759834B (zh) * 2004-09-17 2010-06-23 中国医学科学院医药生物技术研究所 黄连素或其与辛伐他汀联合在制备用于预防或治疗与血脂有关疾病或症状的产品中用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001052822A1 (en) * 2000-01-20 2001-07-26 Chopra Raj K Reduced form of coenzyme q in high bioavailability stable dosage forms and related applications
WO2007090289A1 (en) * 2006-02-09 2007-08-16 National Research Council Of Canada Combinations of botanical extracts for promoting cardiovascular health
WO2014128639A1 (en) * 2013-02-21 2014-08-28 Rondi Andrea Composition for the treatment of metabolic disorders
US20170135995A1 (en) * 2015-11-13 2017-05-18 Shenzhen Hightide Biopharmaceutical, Ltd. Pharmaceutical compositions of berberine with epa and dha, and methods thereof

Also Published As

Publication number Publication date
WO2019073103A1 (es) 2019-04-18
ES2645028B2 (es) 2018-06-04

Similar Documents

Publication Publication Date Title
Papakostas et al. S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial
PH12015502134A1 (en) Mosapride sustained-release preparation for providing pharmacological and clinical effects with once-a-day administration
EA201690102A1 (ru) Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе
BR112015004244A2 (pt) composição médica oralmente administrada
EA201401028A1 (ru) Фармацевтическая композиция, содержащая эмпаглифлозин и лекарственное средство от ожирения
CY1115652T1 (el) Μορφη δοσολογιας που περιεχει δυο δραστικα φαρμακευτικα συστατικα μειγματος σε διαφορετικες φυσικες μορφες
JP2015523407A5 (es)
AR084816A1 (es) Metodos y medicamentos para el tratamiento de la enfermedad de alzheimer
FI2683245T4 (fi) Menetelmiä ja koostumuksia masennuksen hoitamiseen syklobentsapriiniä käyttämällä
CY1114251T1 (el) Χρηση ενος συνδυασμου ο οποιος περιλαμβανει l-kapnitinh ή αλκανοϋλ l-kapnitinh, λιποδιαλυτη βενζοκινονη και ωμεγα-3-πολυακορεστο λιπαρο οξυ για την παρασκευη ενος διαιτητικου συμπληρωματος ή φαρμακου για τη θεραπευτικη αγωγη παθησεων του κερατοειδους
MX2017005163A (es) Composiciones de liberación prolongada de onapristona y métodos.
UY31790A (es) Utilización de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administración de dronedarona
ES2645028A1 (es) Preparación farmacéutica única y estable que contiene berberina, en formulación de liberación lenta, una estatina y ubiquinol para el tratamiento de la enfermedad cardiovascular y los factores de riesgo asociados
RU2014146562A (ru) Композиция, содержащая альфа-липоевую кислоту и гонокиол, для лечения нейропатий
JP2020512408A5 (es)
MX2018011293A (es) Composicion farmaceutica de liberacion prolongada que comprende cisteamina o sal de la misma.
MX2018003890A (es) Composiciones farmaceuticas que contienen un relajante muscular y un antiinflamatorio no esteroideo (aine).
MX2017013643A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y una matriz.
JP2017515858A5 (es)
Rao et al. Development of fast dissolving carbamazepine tablets: effect of functionality of superdisintegrants
PH12016500120A1 (en) Anti-tuberculosis stable pharmaceutical composition in a form of a coated tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation
JP2017530142A5 (es)
PH12018500889A1 (en) Pharmaceutical preparation for delivery of porous material to large intestine or lower part of small intestine
JP2019529554A5 (es)
JP2016514142A5 (es)

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2645028

Country of ref document: ES

Kind code of ref document: B2

Effective date: 20180604

PC2A Transfer of patent

Owner name: FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSP

Effective date: 20181017